Compound Synthesis and Management, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.
Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.
Angew Chem Int Ed Engl. 2022 Sep 26;61(39):e202207831. doi: 10.1002/anie.202207831. Epub 2022 Aug 25.
H O -driven enzymes are of great interest for industrial biotransformations. Herein, we show for the first time that oxalate oxidase (OXO) is an efficient in situ source of H O for one of these biocatalysts, which is known as unspecific peroxygenase (UPO). OXO is reasonably robust, produces only CO as a by-product and uses oxalate as a cheap sacrificial electron donor. UPO has significant potential as an industrial catalyst for selective C-H oxyfunctionalisations, as we confirm herein by testing a diverse drug panel using miniaturised high-throughput assays and mass spectrometry. 33 out of 64 drugs were converted in 5 μL-scale reactions by the UPO with OXO (conversion >70 % for 11 drugs). Furthermore, oxidation of the drug tolmetin was achieved on a 50 mg scale (TON 25 664) with 84 % yield, which was further improved via enzyme immobilization. This one-pot approach ensures adequate H O levels, enabling rapid access to industrially relevant molecules that are difficult to obtain by other routes.
HO 驱动的酶在工业生物转化中具有重要意义。本文首次表明,草酸氧化酶 (OXO) 是一种有效的原位 HO 源,可用于一种被称为非特异性过氧化物酶 (UPO) 的生物催化剂。OXO 相当稳健,只产生 CO 作为副产物,并使用草酸盐作为廉价的牺牲电子供体。UPO 具有作为工业催化剂用于选择性 C-H 氧化官能化的巨大潜力,正如我们通过使用微型高通量测定法和质谱法测试多样化的药物组来确认的那样。用 OXO 的 UPO 将 64 种药物中的 33 种在 5μL 规模的反应中进行了转化(11 种药物的转化率>70%)。此外,在 50mg 规模(TON 25664)上实现了药物托美汀的氧化,产率为 84%,通过酶固定化进一步提高。这种一锅法确保了足够的 HO 水平,使快速获得工业相关的难以通过其他途径获得的分子成为可能。